References
- Jaffee WB, Trucco E, Levy S, et al. Is this urine really negative? A systematic review of tampering methods in urine drug screening and testing. J Subst Abuse Treat. 2007;33(1):33–42. doi: 10.1016/j.jsat.2006.11.008
- BIO-RAD. TOX/seeTM cross-reactivity table by trade name, provided by the manufacturer.
- Melanson SE, Lee-Lewandrowski E, Griggs DA, et al. Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays. Arch Pathol Lab Med. 2006;130(12):1834–1838.
- Smith-Kielland A, Olsen KM, Christophersen AS. False-positive results with Emit II amphetamine/methamphetamine assay in users of common psychotropic drugs. Clin Chem. 1995;41(6 Pt 1):951–952.
- Dahl SG, Strandjord RE, Sigfusson S. Pharmacokinetics and r1elative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol. 1977;11(4):305–310. doi: 10.1007/BF00607681
- Brahm NC, Yeager LL, Fox MD, et al. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm. 2010;67(16):1344–1350. doi: 10.2146/ajhp090477
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi: 10.1038/clpt.1981.154
- Hals PA, Dahl SG. Metabolism of levomepromazine in man. Eur J Drug Metab Pharmacokinet. 1995;20(1):61–71. doi: 10.1007/BF03192290
- van der Zwaan S, Blankespoor RJ, Wolters AM, et al. Additional use of methotrimeprazine for treating refractory agitation in pediatric patients. Intensive Care Med. 2012;38(1):175–176. doi: 10.1007/s00134-011-2414-y